Orion company profile

ORNAV · Nasdaq Helsinki · EUR

Compare Orion
€101.40Change from previous close: −1.36%Absolute change: −€1.40

Close · November 17, 2026

Company profile

Orion has 4,215 employees and is headquartered in Espo, Finland.

Nubeqa, Stalevo, Burana and the Easyhaler inhalers are among the products most associated with Orion Oyj, a Finnish pharmaceutical group that makes medicines for people and animals, as well as active pharmaceutical ingredients sold to other drug makers. Its prescription range covers Parkinson's disease, prostate cancer, asthma and COPD, heart failure, breast cancer and menopausal symptoms, while its veterinary products include Domitor and Sileo. The company also offers contract manufacturing, resells products made by other companies, and sells self-care items such as non-prescription medicines, vitamins and skincare, including online. Its markets include Finland, Scandinavia, the rest of Europe, North America and other regions. Nubeqa is developed under an agreement with Bayer, and oral levosimendan under a licence with Tenax Therapeutics.

In the fiscal year ended 31 December 2025, Orion reported revenue of EUR 1.9 billion, up 22.5% from the previous year, and a net profit of EUR 500.3 million. The company has 4,215 employees and is headquartered in Espo, Finland. Orion Oyj was founded in 1917.

Company facts

Industry
Drug Manufacturers - General
Country
Finland
Headquarters
Orionintie 1A, 02200, Espo
Employees
4,215
Listing
ORNAV · Nasdaq Helsinki
Currency
EUR
ISIN
FI0009014369

Orion and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
OrionORNAVFinland$15.84B4,21538.1%22.0
RecordatiRECItaly$12.09B4,70032.6%21.1
GrifolsGRFSpain$8.71B25,00018.9%16.4
BayerBAYNGermany$61.54B87,77516.5%—
VirbacVIRPFrance$3.27B6,44215.8%19.1
GSKGSKUnited Kingdom$102.04B66,84130.5%18.0

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Orion with its competitors